Precision therapy is designed to selectively target RET alterations

Follows joint letter calling for pharmacists to be able make minor prescription changes

Bispecific antibody targets EGFR and MET mutated tumours

LYT-100 will be evaluated in patients with persistent symptoms caused by COVID-19

Updated Date: Fri, 27 Nov 2020 00:00:00 EST

Updated Date: Fri, 27 Nov 2020 00:00:00 EST

Updated Date: Fri, 27 Nov 2020 00:00:00 EST

Updated Date: Fri, 27 Nov 2020 00:00:00 EST

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 […]

Scientists used human white blood cell membranes to carry two drugs, an antibiotic and an anti-inflammatory, directly to […]